Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Cancer Res. 2020 Dec 22;27(5):1463–1475. doi: 10.1158/1078-0432.CCR-20-3555

Figure 6. Radiologic response to tarloxotinib.

Figure 6.

Baseline imaging obtained prior to dosing with tarloxotinib (150 mg/m2 IV weekly) showed bulky right hilar mass, right pleural effusion, and bilateral adrenal gland lesions (red arrows) (A). A marked tumor response with decreased size of right hilar mass, right pleural effusion, and lesions in the adrenal glands was observed at week 4 (B) and week 12 (C).